These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16986707)

  • 1. [JAK2 mutation in myeloproliferative disorders].
    Inokuchi K
    Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
    [No Abstract]   [Full Text] [Related]  

  • 2. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
    Zhang SJ; Li JY
    Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of the progression of JAK2 V617F positive myeloproliferative neoplasms by single-nucleotide polymorphism array does not reveal a strong chromosomal instability.
    Knoops L; Amyere M; Selleslag D; van Hees J; Girardot M; Michaux L
    Cancer Genet Cytogenet; 2009 Jul; 192(2):102-4. PubMed ID: 19596266
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
    Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
    Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
    Levine RL; Pardanani A; Tefferi A; Gilliland DG
    Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [JAK2 mutation can be used in diagnosis of myeloproliferative diseases].
    Zhu P
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2243-5. PubMed ID: 17064566
    [No Abstract]   [Full Text] [Related]  

  • 7. [Myeloproliferative diseases caused by Jak2 gene mutation].
    Shide K
    Rinsho Ketsueki; 2007 Mar; 48(3):183-7. PubMed ID: 17441474
    [No Abstract]   [Full Text] [Related]  

  • 8. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
    Zhu P
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.
    Skoda R
    Eur J Haematol Suppl; 2007 Oct; (68):5-8. PubMed ID: 17727557
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
    Go RS
    Leukemia; 2007 Sep; 21(9):2051; author reply 2052. PubMed ID: 17597806
    [No Abstract]   [Full Text] [Related]  

  • 11. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
    Siddiqui NS; Ssiddiqui HS; Qurat-Ul-Ain ; Siddiqui SA
    J Coll Physicians Surg Pak; 2010 Jun; 20(6):423. PubMed ID: 20642980
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel JAK2 splicing mutation in neonatal myeloproliferative disorder accompanying congenital anomalies.
    Ohnishi H; Hosoi K; Yoshino H; Sugiura M; Matsushima S; Watanabe T; Bessho F
    Br J Haematol; 2009 Jun; 145(5):676-8. PubMed ID: 19344419
    [No Abstract]   [Full Text] [Related]  

  • 14. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
    Cappetta M; Pérez V; Zubillaga MN; Elizondo V; Manrique G; Prosper I; Boschi S; Bonomi R; Pomoli S; Díaz L; Martínez L; Uriarte MR
    Int J Lab Hematol; 2013 Feb; 35(1):e4-5. PubMed ID: 23062104
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.
    Salmoiraghi S; Montalvo ML; D'Agostini E; Amicarelli G; Minnucci G; Spinelli O; Rambaldi A
    Expert Rev Hematol; 2013 Aug; 6(4):429-39. PubMed ID: 23991929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
    De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
    Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
    [No Abstract]   [Full Text] [Related]  

  • 18. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
    Kodali S; Chen C; Rathnasabapathy C; Wang JC
    Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 (V617F) mutation in healthy individuals.
    Passamonti F; Rumi E; Pietra D; Lazzarino M; Cazzola M
    Br J Haematol; 2007 Feb; 136(4):678-9. PubMed ID: 17223913
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2: implications for diagnosis and classification of myeloproliferative disorders.
    Campbell P
    Lijec Vjesn; 2007 May; 129 Suppl 3():30-2. PubMed ID: 18959057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.